Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
LBT-SA7 (IBT-V02): A Rationally Designed Toxoid Vaccine Poised to Overcome Decades of Failure in the Staphylococcus aureus Field
Executive Summary
The landscape of Staphylococcus aureus vaccine development is a veritable graveyard of promising candidates, marked by decades of high-profile and costly clinical failures. LBT-SA7, a multivalent toxoid vaccine originally developed by Integrated BioTherapeutics (IBT) as IBT-V02 and now advanced by LimmaTech Biologics, represents a significant paradigm shift in this challenging field. This report posits that LBT-SA7 is built upon a scientifically rational and strategically de-risked foundation that directly addresses the fundamental flaws of its predecessors. By targeting key secreted toxins rather than bacterial surface antigens, the vaccine is engineered to neutralize the pathogen’s primary virulence and immune-evasion mechanisms, an approach strongly supported by extensive preclinical data and a growing understanding of S. aureus immunopathology.
The core innovation of LBT-SA7 lies in its mechanism. Historical attempts to develop an S. aureus vaccine have focused on generating opsonizing antibodies against surface antigens, a strategy that has not only failed to confer protection but has, in some cases, been associated with deleterious immune responses and increased mortality in vaccinated individuals who subsequently became infected.[1] LBT-SA7 circumvents this issue by targeting a cocktail of six rationally designed, detoxified proteins (toxoids) that neutralize the pathogen’s pore-forming toxins and superantigens.[5] This approach is designed to disarm the bacterium, protecting host tissues and preserving the integrity of the immune system, thereby allowing for effective clearance.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/12/05 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.